Chugai, Taisho Of Japan To Seek Osteo Drug Approval By Year's End
This article was originally published in PharmAsia News
Japan's Chugai Pharmaceutical and Taisho Pharmaceutical, joint developers of an osteoporosis drug, plan to apply for approval in Japan by the end of this year. The companies made the decision based on Phase III trials that returned positive results. Chugai created the drug that helps promote absorption of calcium and bone formation, and Taisho helped it take the drug through trials that compared it with existing drugs. The two firms have other osteoporosis drugs in joint development. (Click here for more - a subscription may be required
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.